Advertisement

Insulin and Inositol 1,4,5-Trisphosphate Trigger Abnormal Cytosolic Ca2+ Transients and Reveal Mitochondrial Ca2+ Handling Defects in Cardiomyocytes of ob/ob Mice

  1. Jérémy Fauconnier,
  2. Johanna T. Lanner,
  3. Shi-Jin Zhang,
  4. Pasi Tavi,
  5. Joseph D. Bruton,
  6. Abram Katz and
  7. Håkan Westerblad
  1. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
  1. Address correspondence and reprint requests to Håkan Westerblad Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden. E-mail: hakan.westerblad{at}fyfa.ki.se

Abstract

Obesity, insulin resistance, and type 2 diabetes are leading causes of heart failure, and defective cellular Ca2+ handling seems to be a fundamental problem in diabetes. Therefore, we studied the effect of insulin on Ca2+ homeostasis in normal, freshly isolated mouse ventricular cardiomyocytes and whether Ca2+ handling was changed in an animal model of obesity and type 2 diabetes, ob/ob mice. Electrically evoked Ca2+ transients were smaller and slower in ob/ob compared with wild-type cardiomyocytes. Application of insulin (6 or 60 nmol/l) increased the amplitude of Ca2+ transients in wild-type cells by ∼30%, whereas it broadened the transients and triggered extra Ca2+ transients in ob/ob cells. The effects of insulin in ob/ob cells could be reproduced by application of a membrane-permeant inositol trisphosphate (IP3) analog and blocked by a frequently used IP3 receptor inhibitor, 2-aminoethoxydiphenyl borate. In ob/ob cardiomyocytes, insulin increased the IP3 concentration and mitochondrial Ca2+ handling was impaired. In conclusion, we propose a model where insulin increases IP3 in ob/ob cardiomyocytes, which prolongs the electrically evoked Ca2+ release. This, together with an impaired mitochondrial Ca2+ handling, results in insulin-mediated extra Ca2+ transients in ob/ob cardiomyocytes that may predispose for arrhythmias in vivo.

Footnotes

  • A.K. and H.W. have received grant support from Biovitrum Partner.

    • Accepted May 5, 2005.
    • Received January 14, 2005.
| Table of Contents
Advertisement